NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
RESEARCHER PROFILE (Filmed October 2023)
Dr Simon Cook,
Executive Director, Operations
Eudaemon Technologies
Sydney, Australia
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
Motivated by the potential for significant social impact, Dr. Cook is dedicated to overcoming challenges and driving positive change in global health through his work at Eudaemon Technologies.
The innovative approach at Eudaemon Technologies involves replacing latex with tough hydrogel materials, offering a more skin-like feel with no odour, taste, or allergic reactions. Additionally, these materials have the potential to integrate small molecule drugs, presenting opportunities for enhanced user experience and additional protective measures against STIs.
Beyond his professional endeavours, Dr. Cook enjoys music, particularly playing the guitar, bass guitar, and drums. He also maintains an active lifestyle through sports including soccer and squash.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Mental health research on first responders in regional, rural and remote Australia
Dr Rikki Jones has been awarded to date a total of over $430,000 in research funding. She is currently leading four large national research teams focusing on rural health and sustainable rural health workforce (include mental health of first responders, sexual violence in rural Australia, virtual simulated nursing placements, and nursing students experience with online learning, connection and transitioning to practice).
-
Clinical guidelines for diagnostics and early intervention in Primary Aldosteronism
Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Associate Professor Jun Yang’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
